New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

These variations reflect differences in reimbursement policies for Lp apheresis rather than differences in the prevalence of drug-refractory familial hypercholesterolemia (FH), the main indication ...

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH) ...

SHANGHAI, June 6, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug ...

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's ...

XYolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the US Food and Drug Administration (FDA) has cleared the company’s ...

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...